基于循环肿瘤DNA评估肝癌或结直肠癌肝转移术后疾病进展的随机对照试验研究方案
本研究为随机对照试验,计划纳入300例接受肝切除或肝移植的肝细胞癌(HCC)或结直肠癌肝转移(CRLM)患者,按2:1随机分配至ctDNA监测组或标准随访组。ctDNA在基线、术后1个月和6个月三个时间点检测,并与肿瘤组织NGS突变谱比较,随访24个月。主要终点为ctDNA定义的复发,次要终点包括无复发生存、总生存、复发检测时间、患者报告结局和成本效果。
要点
- ctDNA监测可能较标准影像和标志物更早发现HCC或CRLM术后微小残留病和复发。
- 研究采用2:1随机设计,ctDNA组在基线、术后1个月和6个月检测,随访24个月。
- 主要终点为ctDNA定义的复发,同时评估生存、检测时间和成本效果。
核心结论
- 该试验旨在评估ctDNA监测能否在HCC或CRLM肝切除或肝移植后更早发现复发并改善临床决策。
研究设计与样本
- 随机对照试验,计划纳入300例接受肝切除或肝移植的CRLM或HCC患者。
- 参与者按2:1随机分配至ctDNA监测组或标准随访组。
- ctDNA在基线、术后1个月和6个月三个预设时间点检测,并与肿瘤组织NGS突变谱比较。
- 所有患者随访24个月,采用影像、肿瘤标志物和生活质量评估。
关键数值与推荐
- 主要终点为ctDNA定义的复发。
- 次要终点包括无复发生存、总生存、复发检测时间、患者报告结局和成本效果。
- 试验注册号ClinicalTrials.gov NCT07001085,注册于2025年。
临床怎么用
- 若ctDNA监测被证实可更早发现复发,可能支持术后更早的治疗干预和个体化随访策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/AIM: Hepatocellular carcinoma (HCC) and colorectal cancer liver metastases (CRLM) carry high recurrence rates after surgery or transplantation. Conventional imaging and biomarkers have limited sensitivity for detecting minimal residual disease (MRD). Circulating tumor DNA (ctDNA) is a promising biomarker that may enable earlier recurrence detection compared with standard methods. The aim of this randomized controlled trial is to evaluate the clinical utility of ctDNA monitoring in the early detection of disease recurrence and its impact on monitoring progression in patients undergoing liver resection or transplantation for HCC and CRLM. METHODS: This randomized, controlled trial will enroll 300 patients undergoing liver resection or transplantation for CRLM or HCC. Participants will be randomized 2:1 to ctDNA monitoring or standard follow-up. ctDNA will be analyzed at three predefined time points (baseline, 1 month, and 6 months postoperatively) and compared with tumor tissue mutation profiles generated by next-generation sequencing (NGS). All patients will be followed for 24 months with imaging, tumor markers, and quality-of-life assessments. The primary endpoint is ctDNA-defined recurrence. Secondary endpoints include recurrence-free survival, overall survival, time to recurrence detection, patient-reported outcomes, and cost-effectiveness. DISCUSSION: This study will assess whether ctDNA-guided monitoring enables earlier recurrence detection and improves clinical decision-making after liver resection or transplantation. Incorporating ctDNA into surveillance may support earlier therapeutic intervention, optimize follow-up strategies, and enhance long-term outcomes. TRIAL REGISTRATION: ClinicalTrials.gov NCT07001085. Registered on 2025.
引用
- Górzyńska I, Kornasiewicz O, Koniczka A, et al. Circulating tumor DNA-based assessment of disease progression after liver resection or transplantation for metastatic colorectal cancer or hepatocellular carcinoma-study protocol for a randomized, controlled trial. Trials. 2026. PMID: 42185926. doi:10.1186/s13063-026-09790-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。